Table 3.
Multivariate analysis of prognostic factor for disease-free survival in patients undergoing sentinel lymph node biopsy
| Variable | SLN-negative (TN and FN) |
ALN-positive (FN and TP) |
||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | p-value | Hazard ratio | 95% CI | p-value | |
| Age > 50 yr | 1.02 | 0.35-1.12 | 0.116 | 1.21 | 0.66-2.20 | 0.526 |
| Tumor size > 2 cm | 1.86 | 1.17-2.96 | 0.009 | 2.20 | 1.17-4.11 | 0.014 |
| N stage, N ≥ 2 | - | - | - | 2.13 | 1.12-4.06 | 0.022 |
| Histologic grade | 1.02 | 0.58-1.78 | 0.941 | 1.56 | 0.88-3.05 | 0.118 |
| LVI | 0.99 | 0.35-2.80 | 0.989 | 0.71 | 0.35-1.42 | 0.330 |
| HR positivity | 0.50 | 0.62-3.89 | 0.337 | 0.91 | 0.36-2.29 | 0.835 |
| HER2, positive | 0.51 | 0.24-1.08 | 0.079 | 0.59 | 0.29-1.22 | 0.157 |
| False-negative | 2.51 | 1.42-4.42 | 0.002 | 0.64 | 0.33-1.25 | 0.191 |
| Breast surgery, TM | 0.67 | 0.39-1.15 | 0.148 | 0.97 | 0.48-1.97 | 0.925 |
| Chemotherapy | 0.75 | 0.41-1.26 | 0.339 | 0.75 | 0.62-1.64 | 0.862 |
| Anti-hormone therapy | 0.83 | 0.29-2.36 | 0.725 | 0.61 | 0.27-1.40 | 0.250 |
SLN, sentinel lymph node; TN, true-negative; FN, false-negative; ALN, axillary lymph node; TP, true-positive; CI, confidence interval; LVI, lymphovascular invasion; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TM, total mastectomy.